Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease

作     者：Oguzhan Ozturk Yasar Colak Ebubekir Senates Yusuf Yilmaz Celal Ulasoglu Levent Doganay Seyma Ozkanli Yasemin Musteri Oltulu Ender Coskunpinar Ilyas Tuncer 

作者机构：Department of GastroenterologyGoztepe Teaching and Research HospitalIstanbul Medeniyet University Department of GastroenterologyMarmara University School of MedicineIstanbulTurkey Institute of GastroenterologyMarmara University Department of PathologyGoztepe Teaching and Research HospitalIstanbul Medeniyet University Department of Molecular MedicineInstitute of Experimental Medicine ResearchIstanbul University 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第26期

页      面：8096-8102页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Insulin resistance Liver fibrosis Metabolicsyndrome Nonalcoholic fatty liver disease Steatohepatitis 

摘      要：AIM: To analyze the relationship between the serum lectin-like oxidized low-density lipoprotein receptor-1(LOX-1) levels and clinical and histopathological features of biopsy-confirmed nonalcoholic fatty liver disease(NAFLD) ***: Fifty-three consecutive,biopsy-proven NAFLD patients(31 males and 22 females,mean age 42.5 ± 9.6 years) and 26 age- and gender-matched,healthy controls(14 males and 12 females,mean age 39 ± 10.7 years) were *** patientswith NAFLD were consecutive patients who had been admitted to the hepatology outpatient clinic within the last year and had been diagnosed with NAFLD as the result of liver *** healthy controls were individuals who attended the outpatient clinic for routine health control and had no known chronic *** histological evaluation was conducted according t o t he N AF LD ac t ivi ty scoring syst em recommended by The National Institute of Diabetes and Digestive and Kidney Diseases Nonalcoholic Steatohepatitis Clinical Research *** serum LOX-1 levels were measured using an ELISA kit(Life Science ***,Catalog No.E1859Hu) in both patients and healthy controls.A receiver operating characteristic(ROC) curve analysis was used to identify the optimal cutoff value of LOX-1 and thereby distinguish between patients with nonalcoholic steatohepatitis(NASH) and healthy controls.A P-value 0.05 was considered statistically ***: NAFLD and healthy control groups were similar in terms of age and *** patients consisted of 8 patients with simple steatosis(15%),27 with borderline NASH(51%) and 18 with definitive NASH(34%).Metabolic syndrome was found in 62.2% of the patients with *** mean serum LOX-1 level in biopsy-proven NAFLD patients was 8.49 ± 6.43 ng/m L compared to 4.08 ± 4.32 ng/m L in healthy controls(P = 0.001).The LOX-1 levels were significantly different between controls,simple steatosis and NASH(borderline+definite) cases(4.08 ± 4.32 ng/m L,6.1 ± 6.16 ng/